These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38229453)

  • 1. Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
    Hope DCD; Ansari S; Choudhury S; Alexiadou K; Tabbakh Y; Ilesanmi I; Lazarus K; Davies I; Jimenez-Pacheco L; Yang W; Ball LJ; Malviya R; Reglinska B; Khoo B; Minnion J; Bloom SR; Tan TM
    Diabetes Obes Metab; 2024 Apr; 26(4):1479-1491. PubMed ID: 38229453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
    Yazawa R; Ishida M; Balavarca Y; Hennige AM
    Diabetes Obes Metab; 2023 Jul; 25(7):1973-1984. PubMed ID: 36974349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
    Jungnik A; Arrubla Martinez J; Plum-Mörschel L; Kapitza C; Lamers D; Thamer C; Schölch C; Desch M; Hennige AM
    Diabetes Obes Metab; 2023 Apr; 25(4):1011-1023. PubMed ID: 36527386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
    Asano M; Sekikawa A; Kim H; Gasser RA; Robertson D; Petrone M; Jermutus L; Ambery P
    Diabetes Obes Metab; 2021 Aug; 23(8):1859-1867. PubMed ID: 33908687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.
    Winther JB; Holst JJ
    Diabetes Obes Metab; 2024 Sep; 26(9):3501-3512. PubMed ID: 38853300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y
    Yuan Y; Yan Z; Lao Q; Jiang N; Wu S; Lu Q; Han J; Zhao S
    Eur J Med Chem; 2023 Feb; 247():115036. PubMed ID: 36571995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
    Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
    Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Urva S; Coskun T; Loh MT; Du Y; Thomas MK; Gurbuz S; Haupt A; Benson CT; Hernandez-Illas M; D'Alessio DA; Milicevic Z
    Lancet; 2022 Nov; 400(10366):1869-1881. PubMed ID: 36354040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
    Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
    Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.
    Friedrichsen MH; Endahl L; Kreiner FF; Goldwater R; Kankam M; Toubro S; Nygård SB
    Mol Metab; 2023 Dec; 78():101801. PubMed ID: 37690519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives in weight control in diabetes - Survodutide.
    Klein T; Augustin R; Hennige AM
    Diabetes Res Clin Pract; 2024 Jan; 207():110779. PubMed ID: 37330144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients.
    Singh S; Garg A; Tantry US; Bliden K; Gurbel PA; Gulati M
    Curr Probl Cardiol; 2024 Mar; 49(3):102403. PubMed ID: 38237815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
    Ji L; Jiang H; Cheng Z; Qiu W; Liao L; Zhang Y; Li X; Pang S; Zhang L; Chen L; Yang T; Li Y; Qu S; Wen J; Gu J; Deng H; Wang Y; Li L; Han-Zhang H; Ma Q; Qian L
    Nat Commun; 2023 Dec; 14(1):8289. PubMed ID: 38092790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.